Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Weight loss ads referred to FTC

This article was originally published in The Tan Sheet

Executive Summary

Health Center For Better Living's advertising for its Metabolene weight loss formula was referred to the Federal Trade Commission by the Electronic Retailing Self-Regulation Program after the Naples, Fla.-based firm failed to respond to an inquiry, the Council of Better Business Bureau's arm says Aug. 29. ERSP reviewed HCBL's ad claims for Metabolene, including "effortlessly melt away 30 lbs. in 30 days," after receiving an anonymous complaint. The CBBB group also asked the firm to substantiate consumer claims included in its ads that are "in contravention of the criteria" in FTC's "Red Flag - Bogus Weight Loss Claims" guide. After firms fail to comply with recommendations from advertising reviews or respond to inquires, the self-regulatory arms of CBBB refer them to the FTC, which give the cases high priority in its consumer protection enforcement (1"The Tan Sheet" June 4, 2007, p. 11)...

You may also be interested in...

Do Not Disrespect NAD: FTC Stresses Compliance With Self-Regulatory Groups

The decision by the maker of Sunpill sunscreen tablets not to comply with the National Advertising Division's recommendations to change its advertising claims is an uncommon response that will get the Federal Trade Commission's attention, Lesley Fair, senior attorney in FTC's Division of Consumer Education, says

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts